ASEA, LLC
 | |
| Private | |
| Founded | 2007 |
| Headquarters | Salt Lake City, Utah, United States |
Key people |
Charles F. Funke, CEO Jarom Webb, President[1] |
| Website |
aseaglobal |
ASEA, LLC is a privately owned international direct selling and multi-level marketing company founded in 2007 and headquartered in Salt Lake City, Utah.[2] It has previously been known as Medical Immune Research, Inc. and ASEA, Inc.[3]
Overview
ASEA was founded by Verdis Norton, James Pack, and Tyler Norton. The current management consists of Charles F. Funke, CEO, Jarom Webb, President,[1] and Kurt Richards, Executive Vice President.[4]
History
The company officially launched in 2009. Currently, it has approximately 30,000 active associates.[5] In 2013, ASEA, LLC moved its operations to a 33,000 square foot production facility which produces 15,000 cases of ASEA a week.[6]
Products
ASEA’s first product was a liquid supplement initially also named ASEA, and currently known as ASEA Redox Supplement. In 2014, RENU 28, a skin revitalization gel product, was added to its product lineup.[7]
While the primary ingredients created in the original MDI-P solution are found in the current ASEA Redox Supplement and RENU 28 products, the processes and outputs differ. All prior patents from the previous company have expired. New patents that cover the proprietary composition and production processes used to produce ASEA and RENU 28 have been filed and issued.[8][9][10][11][12][13]
In 2015, ASEA partnered with BioAgilytix Labs to work in unison with their internal product teams to monitor the quality of the manufacturing process and give the scientific validity of the nature of the products. Specializing in biomarker testing, BioAfilytix validates the existence of reactive oxygen in the product. To maintain the BioAgilytix certification, ASEA provides a weekly product sampling for a scientific assay to substantiate the existence of reactive oxygen molecules in ASEA redox products and for product quality.[14]
History
ASEA is based on technology developed and patented by Medical Discoveries, Inc, a publicly traded company (MLSC). MDI-P was a clear, colorless liquid generated by electrolysis of a sterile saline. It contained highly reactive chlorine and oxygen species, including HOCl, OCl−, Cl−, Cl2, and O3. It was tested for its microbicidal properties and was found effective against Staphylococcus aureus, Pseudomonas aeruginosa, Legionella pneumophila, and Candida albicans and is considered to be a very fast-acting, broad-spectrum microbicidal solution.[15][16] While the primary ingredients created in the original MDI-P solution are found in the current ASEA Redox Supplement and RENU 28 products, the processes and outputs differ. All prior patents from the previous company have expired. New patents that cover the proprietary composition and production processes used to produce ASEA and RENU 28 have been filed and issued.[8][9][10][11][12][13]
MDI went up for sale in 2007, and Verdis Norton, who sat on the board at the time, decided to gather other investors and purchase the technology. They made the decision to create a consumable product in a liquid form that could be classified as a supplement.[8][9][10][11][12][13]
Norton and his partners funded research to differentiate the new product from its pharmaceutical-grade predecessor into something consumable, believing that recreating redox signaling molecules outside the human body and producing them in a consumable product would optimize cellular function and overall health and wellness.[8][9][10][11][12][13]
Under the company name of ASEA, they began selling the product in 2009 with an official launch in 2010. Currently, ASEA has approximately 30,000 active associates. In 2013, ASEA, LLC moved its manufacturing operations to a 33,000 square-foot production facility, which is FDA registered, NSF certified, and GMP compliant and produces 15,000 cases of ASEA Redox Supplement per week.[8][9][10][11][12][13]
References
- 1 2 "Leadership". ASEA, LLC. Retrieved 20 May 2015.
- ↑ "ASEA, LLC". BBB. Retrieved 20 May 2015.
- ↑ "ASEA, LLC". State of Utah. Retrieved 20 May 2015.
- ↑ "Kurt Richards". Bloomberg Business. Retrieved 1 June 2015.
- ↑ Workman, Jennifer (1 February 2014). "ASEA: Building a Legacy". Direct Selling News. Retrieved 20 May 2015.
- ↑ "ASEA". Direct Selling News Blog. Retrieved 20 May 2015.
- ↑ "RENU 28". ASEA, LLC. Retrieved 20 May 2015.
- 1 2 3 4 5 "ASEA Trademark of Medical Immune Research, Inc. - Registration Number 3613618 - Serial Number 77456357 :: Justia Trademarks". trademarks.justia.com. Retrieved 2016-04-22.
- 1 2 3 4 5 "Entity Details: ASEA, LLC - Utah Business Search - Utah.gov". secure.utah.gov. Retrieved 2016-04-22.
- 1 2 3 4 5 "Patent Database Search Results: "Norton Verdis" AND AN/"REOXCYN DISCOVERIES" in US Patent Collection". patft.uspto.gov. Retrieved 2016-04-22.
- 1 2 3 4 5 "Listing Category Search Page | NSF International". info.nsf.org. Retrieved 2016-04-22.
- 1 2 3 4 5 "ASEA Celebrates Its Fifth Anniversary With NSF Certification, Product Validation and the Launch of the ASEA Advancing Life Foundation". Reuters. 2015-05-06. Retrieved 2016-04-22.
- 1 2 3 4 5 "ASEA Manufacturing Plant Open House". Curtis Miner Architecture. 2013-08-24. Retrieved 2016-04-22.
- ↑ "Reactive Oxygen | BioAgilytix". BioAgilytix. Retrieved 2016-04-22.
- ↑ Aldona L. Baltch; Raymond P. Smith; Mary A. Franke; William J. Ritz; Phyllis Michelsen; Lawrence H. Bopp; Jaswant K. Singh (June 2000). "Microbicidal activity of MDI-P against Candida albicans, Staphylococcus aureus, Pseudomonas aeruginosa, and Legionella pneumophila". American Journal of Infection Control 28 (3): 251–257.
- ↑ Aldona L. Baltch; Raymond P. Smith; Mary A. Franke; William J. Ritz; Phyllis Michelsen; Lawrence H. Bopp; Jaswant K. Singh (June 2000). "Microbicidal activity of MDI-P against Candida albicans, Staphylococcus aureus, Pseudomonas aeruginosa, and Legionella pneumophila". American Journal of Infection Control 28 (3): 251–257.